Case Control Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Apr 6, 2021; 9(10): 2181-2191
Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2181
Figure 3
Figure 3 Effects of Iguratimod on interleukin-6, interleukin-1β, transforming growth factor-β and interleukin-4 in joint effusion fluid. Compared with that before treatment, aP < 0.05. IL: Interleukin; TFG-β: Transforming growth factor-β; TNF-α: Tumor necrosis factor-α.